文献速递外周动脉疾病

晚期伤口、缺血和足部感染分期与BEST-CLI试验中的不良结局相关

Advanced Wound, Ischemia, and Foot Infection stage is associated with poor outcomes in the BEST-CLI trial.
PubMed 文献 · J Vasc Surg · 2024-12-03

基于BEST-CLI前瞻性随机试验的意向性治疗分析,纳入1568例慢性肢体威胁性缺血患者,评估WIfI分期与长期结局的关联。结果显示WIfI 4期和3期较1/2期与更高的3年大截肢、死亡、截肢/死亡及主要不良肢体事件/死亡风险相关;在队列1中,开放手术在各WIfI分期下主要不良肢体事件/死亡均较低。

要点

  • WIfI 4期和3期较1/2期与3年大截肢率更高相关(21.4%、16.2% vs 10.7%)。
  • 风险校正后,WIfI 4期大截肢风险HR 2.06(95%CI 1.44-2.96,P<.001),3期HR 1.62(95%CI 1.1-2.37,P=.013)。
  • 队列1中开放手术在各WIfI分期下主要不良肢体事件/死亡均较低。

核心结论

  • 在BEST-CLI中,WIfI分期与CLTI血运重建后的大截肢、死亡和MALE/死亡强烈相关。
  • 队列1患者(术前有 adequate 单段大隐静脉)在各WIfI分期下开放手术的MALE/死亡较低。
  • WIfI评分在前瞻性多中心试验中的验证强化了其在共同决策、知情同意和预后判断中的重要性。

研究设计与样本

  • BEST-CLI试验为前瞻性随机试验,比较开放手术血运重建(OPEN)与腔内血运重建(ENDO)。
  • 本分析为意向性治疗分析,评估WIfI分期与长期结局的关联。
  • 患者前瞻性分配至两个队列,分别包括有和无 adequate 单段大隐静脉的患者。
  • 共分析1568例患者,占整个试验人群的86%。
  • 本分析主要结局为大截肢。

主要发现

  • WIfI 4期、3期和1/2期分别占35.5%、29.6%和34.9%。
  • 队列1有1223例患者(OPEN 606例,ENDO 617例),队列2有345例患者(OPEN 172例,ENDO 173例)。
  • 未校正Kaplan-Meier分析中,3年时WIfI 4期和3期较1/2期与大截肢率更高相关(21.4%、16.2% vs 10.7%),P<.05。
  • 未校正分析中,3年时WIfI 4期和3期较1/2期与死亡率更高相关(33.5%、35.7% vs 24.6%),P<.05。
  • 未校正分析中,3年时WIfI 4期和3期较1/2期与截肢/死亡(44.9%、44.5% vs 31.3%)、MALE/死亡(34.4%、33.9% vs 29.5%)和再干预/截肢/死亡(69.9% vs 69% vs 60.4%)更高相关,P<.05。

关键数值与推荐

  • 风险校正分析中,较WIfI 1/2期,WIfI 4期与大截肢相关(HR 2.06;95%CI 1.44-2.96;P<.001),WIfI 3期与大截肢相关(HR 1.62;95%CI 1.1-2.37;P=.013)。
  • 风险校正分析中,较WIfI 1/2期,WIfI 4期与死亡相关(HR 1.3;95%CI 1.03-1.63;P=.027),WIfI 3期与死亡相关(HR 1.42;95%CI 1.13-1.79;P=.003)。
  • 风险校正分析中,较WIfI 1/2期,WIfI 4期与MALE/死亡相关(HR 1.29;95%CI 1.02-1.63;P=.036)。
  • 风险校正分析中,较WIfI 1/2期,WIfI 4期与再干预/截肢/死亡相关(HR 1.28;95%CI 1.09-1.50;P=.03),WIfI 3期与再干预/截肢/死亡相关(HR 1.22;99%CI 1.03-1.43;P=.018)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为WIfI评分在前瞻性多中心试验中的验证强化了其在共同决策、知情同意和预后判断中的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Wound, Ischemia, and foot Infection (WIfI) staging was established to provide objective classification in patients with chronic limb-threatening ischemia (CLTI) and to predict 1-year major amputation risk. Our goal was to validate WIfI staging using data from the Best Endovascular vs Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial. METHODS: Data from the BEST-CLI Trial, a prospective randomized trial comparing surgical revascularization (OPEN) and endovascular revascularization (ENDO), were used to assess the association of WIfI stage on long-term outcomes in an intention-to-treat analysis. Patients were prospectively allocated to two cohorts, which included patients with and without adequate single-segment greater saphenous vein, respectively. The primary outcome of this analysis was major amputation. RESULTS: There were 1568 patients analyzed, representing 86% of the entire trial population; of these 35.5%, 29.6%, and 34.9% were categorized as WIfI stage 4, WIfI stage 3, and WIfI stage 1/2, respectively. There were 1223 patients (606 OPEN, 617 ENDO) and 345 patients (OPEN 172, ENDO 173) in cohorts 1 and 2, respectively. On unadjusted Kaplan-Meier analysis, WIfI clinical stages 4 and 3, compared with WIfI stage 1/2, were associated with higher rates of major amputation (21.4%, 16.2% vs 10.7%), death (33.5%, 35.7% vs 24.6%), amputation/death (44.9%, 44.5% vs 31.3%), major adverse limb events (MALEs)/death (34.4%, 33.9% vs 29.5%), and reintervention/amputation/death (69.9% vs 69% vs 60.4%) (P < .05 for all) at 3 years. On risk-adjusted analysis, compared with WIfI stage 1/2, major amputation was associated with WIfI stage 4 (hazard ratio [HR], 2.06; 95% confidence interval [CI], 1.44-2.96; P < .001) and WIfI stage 3 (HR, 1.62; 95% CI, 1.1-2.37; P = .013) stages. Death was associated with WIfI stage 4 (HR, 1.3; 95% CI, 1.03-1.63; P = .027) and WIfI stage 3 (HR, 1.42; 95% CI, 1.13-1.79; P = .003). MALE/death was associated with WIfI stage 4 (HR, 1.29; 95% CI, 1.02-1.63; P = .036. Reintervention amputation/death was associated with WIfI stage 4 (HR, 1.28; 95% CI, 1.09-1.50; P = .03) and WIfI stage 3 (HR, 1.22, 99% CI 1.03-1.43) ; P = .018). When examining OPEN vs ENDO revascularization by each WIfI stage, OPEN intervention was favored in cohort 1 for MALE/death for each stage. CONCLUSIONS: In BEST-CLI, WIfI stage was strongly associated with major amputations, death, and MALEs/death after revascularization for CLTI. Cohort 1 patients, with an adequate preoperative single segment greater saphenous vein, had lower MALE/death with OPEN intervention across all WIfI stages. This validation of WIfI score in a prospective multicenter trial reinforces its importance in shared-decision making, informed consent, and prognostication.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Siracuse JJ, Farber A, Menard MT, et al. Advanced Wound, Ischemia, and Foot Infection stage is associated with poor outcomes in the BEST-CLI trial. J Vasc Surg. 2024. PMID: 39638100. doi:10.1016/j.jvs.2024.11.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。